跳至主要内容

Anti-drug Antibody Preparation

 Medicilon has rich experience in ADA development and has successfully delivered more than 100 projects. Medicilon can provide high-affinity and specific polyclonal anti-drug antibody development services with short development cycles and low costs.

  • Immunogenicity refers to the immune response generated by the immune system against drugs entering the human body. The immune response produces anti-drug antibodies (ADA) that specifically bind to drug molecules. In the process of drug development, especially for macromolecular drugs, small molecule and peptide drugs, and even related adjuvants, they may directly or indirectly cause a large immunogenic reactions. Mild reactions may lead to the termination of projects in the preclinical or clinical stages, resulting in the loss of early economic investments. Severe reactions may reduce drug efficacy, cause allergic reactions, and even pose a threat to life safety.
    According to current FDA guidelines, all serious immune responses, including acute hypersensitivity and neutralizing antibody responses, must be excluded during drug development. Therefore, ADA (Anti-Drug-Antibody)—effective detection in PK research, that is, systematic and scientific completion of ADA detection is an urgent issue in PK research.
    The evaluation of immunogenicity is mainly carried out by anti-drug antibody (anti-drug antibody, ADA) analysis method. In order to effectively evaluate the immunogenicity of antibody drugs in preclinical and clinical research, it is particularly important to develop reliable ADA assessment and detection methods.. Analytical techniques include ELISA, ECL, SPR, RIA, MSD, etc., and one or several combinations can be flexibly adopted. Currently, the most commonly used techniques are ECL and MSD.
    High-sensitivity and diverse polyclonal anti-drug antibodies can be used as a positive reference in immunogenicity studies, simulating the situation of ADA production in the human body. They can also specifically detect the level of antibody drugs in the body, making them important reagents for pharmacokinetic studies. Therefore, as essential tools in the development of antibody drugs, anti-drug antibodies are not only indispensable for clinical applications but also widely used in clinical stages.
    Medicilon has rich experience in ADA development and has successfully delivered more than 100 projects. Medicilon can provide high-affinity and specific polyclonal anti-drug antibody development services with short development cycles and low costs.
Development process
  • （1）Antigen preparation
    Antigen detection (1-2 days)Antigen reviewAntigen preparation (2 weeks)Conjugation or enzymatic cleavage of the full-length antibody drug provided by the client.
  • （2）Immunization and serum testing
    Immunization and serum titer testing (8 weeks)Blood collection before immunization, animal immunization, titer testing, final blood collection, provide immunization schedule and titer test report; titer meets ≥1:729,000       
  • （3）Antibody purification
    Antibody purification (2 weeks)Protein A purificationAntigen affinity chromatographyTotal human IgG de-cross-purified (optional)Other proteins to cross-purify (optional)       
  • （4）Antibody detection
    Antibody identification (1 week)SDS-PAGE purity analysis, UV concentration determinationTotal human IgG cross-reactivity;<2% cross-reactivity
  • （5）Delivery
    Delivery (12 weeks)Purified antibody, titer ≥1:243,000, quantity (optional)COAProject Development Detailed Report       

Advantage
  • Rich experience: More than 10 years of service development experience, one-to-one communication to customize projects, real-time feedback on experimental situations.Various types: Full-length antibodies, antibody fragments, small molecule drugs, peptide drugs, ADC drug conjugates, vaccines, etc.High quality:Guaranteed delivery sensitivity, cross-reactivity meeting regulatory requirements for PK/ADA detection antibodies.Various purification methods:Protein A/G, antigen affinity, Human IgG, isotype IgG, interfering protein, etc.

Case
  • Case 1-ADC Drug

    ADC drug- Serum titer.jpg


    Serum titer

    ADC drug-Antibody titer after purification.png


    Antibody titer after purification

  • Case 2-Antibody drug human IgG decrossover

    Antibody drug human IgG decrossover-Serum titer.png


    Serum titer

    Antibody drug human IgG decrossover-Antibody titer after purification.png


    Antibody titer after purification

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文